Abstract
Objectives The objective of this study was to evaluate potential safety and clinical benefit of low-molecular-weight dextran (dextran) use in patients undergoing total pancreatectomy with islet auto transplantation (TPIAT). Methods We evaluated 124 children undergoing TPIAT at a single institution, either with (n = 72) or without (n = 52) perioperative dextran infusion. Data on islet graft function and postoperative complications were collected through electronic medical records and patient-reported outcomes from research questionnaires. Results Islet graft failure was less likely at 1 year (odds ratio, 0.186; 95% confidence interval, 0.04-0.65) and 2 years (odds ratio, 0.063; 95% confidence interval, 0.003-0.35) post-TPIAT in the dextran group. This finding remained significant at 2 years in multivariate logistic regression modeling adjusting for islet mass, body surface area, and sex. Likewise, in multivariate regression, the odds of partial islet graft function were higher at 1 and 2 years in the dextran group. Dextran use was overall safe, although it did lead to a higher incidence of postoperative bleeding requiring blood transfusions (P < 0.001). Conclusions These findings suggest that dextran use may increase the likelihood for sustained post-TPIAT islet graft function, potentially mitigating severity of postoperative diabetes for these children.
Original language | English (US) |
---|---|
Pages (from-to) | 774-780 |
Number of pages | 7 |
Journal | Pancreas |
Volume | 49 |
Issue number | 6 |
DOIs | |
State | Published - Jul 1 2020 |
Bibliographical note
Publisher Copyright:Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Keywords
- TPIAT
- dextran
- pediatric
- transplant
PubMed: MeSH publication types
- Journal Article